<code id='EDE0CB3DEB'></code><style id='EDE0CB3DEB'></style>
    • <acronym id='EDE0CB3DEB'></acronym>
      <center id='EDE0CB3DEB'><center id='EDE0CB3DEB'><tfoot id='EDE0CB3DEB'></tfoot></center><abbr id='EDE0CB3DEB'><dir id='EDE0CB3DEB'><tfoot id='EDE0CB3DEB'></tfoot><noframes id='EDE0CB3DEB'>

    • <optgroup id='EDE0CB3DEB'><strike id='EDE0CB3DEB'><sup id='EDE0CB3DEB'></sup></strike><code id='EDE0CB3DEB'></code></optgroup>
        1. <b id='EDE0CB3DEB'><label id='EDE0CB3DEB'><select id='EDE0CB3DEB'><dt id='EDE0CB3DEB'><span id='EDE0CB3DEB'></span></dt></select></label></b><u id='EDE0CB3DEB'></u>
          <i id='EDE0CB3DEB'><strike id='EDE0CB3DEB'><tt id='EDE0CB3DEB'><pre id='EDE0CB3DEB'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:5
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Science's Marcia McNutt, trailblazer for women, encounters sexism scandal
          Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

          MarciaMcNutthasbeentappedtoleadtheNationalAcademyofSciences.DrewAngererforSTATThefirstwomantappedtol

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

          DarronCummings/APLONDON—AU.K.governmentagencyonTuesdaysaidthatitwon’trecommendEliLilly’sMounjaro—par